Adarsh Vennepureddy - Hematologist ...

Dr. Adarsh Vennepureddy

Claim this profile

Aultman Health Foundation

Studies Colorectal Cancer
Studies Colon Cancer
9 reported clinical trials
30 drugs studied

Area of expertise

1

Colorectal Cancer

Adarsh Vennepureddy has run 3 trials for Colorectal Cancer. Some of their research focus areas include:

Stage III
Stage II
MLH1 positive
2

Colon Cancer

Adarsh Vennepureddy has run 2 trials for Colon Cancer. Some of their research focus areas include:

Stage III
Stage II
MLH1 positive

Affiliated Hospitals

Image of trial facility.

Aultman Health Foundation

Image of trial facility.

Aultman Alliance Community Hospital

Clinical Trials Adarsh Vennepureddy is currently running

Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

Recruiting

1 award

Phase 2

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

More about Adarsh Vennepureddy

Clinical Trial Related

2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Adarsh Vennepureddy has experience with

  • Binimetinib
  • Fulvestrant
  • Paclitaxel
  • Oxaliplatin
  • Selumetinib Sulfate
  • Ipatasertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Adarsh Vennepureddy specialize in?

Is Adarsh Vennepureddy currently recruiting for clinical trials?

Are there any treatments that Adarsh Vennepureddy has studied deeply?

What is the best way to schedule an appointment with Adarsh Vennepureddy?

What is the office address of Adarsh Vennepureddy?

Is there any support for travel costs?